- Summit Therapeutics (NASDAQ:SMMT) shares perked up Wednesday after Evercore ISI launched its protection with an Outperform suggestion, arguing that the corporate’s lead asset developed with Chinese language biotech Akeso (OTCPK:AKESF) will probably be a direct rival to Merck’s (NYSE:MRK) blockbuster Keytruda.
- “We
